Research programme: MIF inhibitors - Novartis
Alternative Names: AVP-13748; AVP-28225Latest Information Update: 04 Nov 2017
At a glance
- Originator Avanir Pharmaceuticals
- Developer Novartis
- Class Small molecules
- Mechanism of Action Macrophage migration-inhibitory factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Inflammation
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Inflammation in USA (PO)
- 13 Jul 2010 Preclinical development is ongoing in USA
- 30 Mar 2007 Preclinical development is ongoing